Related Experiment Video
Updated: Jan 5, 2026
Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones
Published on: November 30, 2016
Molecular Approaches to Metastatic Colorectal Cancer: Better Diagnosis - Better Treatment?
Thomas Seufferlein1, Carolina Simões2, Fernando Kude3
1Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany.
Abstract:
Molecular diagnostics of metastatic colorectal cancer (mCRC) are coming of age. Whereas for many years RAS mutations were the only relevant molecular alterations examined in mCRC, nowadays the BRAF, HER2, and microsatellite instability status of a given tumor is gaining importance, since it has not only prognostic relevance but opens new avenues for therapeutic approaches. This review summarizes the recent advances in molecular approaches to mCRC and their therapeutic consequences and discusses novel approaches for molecular diagnostics in mCRC.
Insights
Molecular diagnostics for metastatic colorectal cancer (mCRC) are advancing. Beyond RAS mutations, BRAF, HER2, and microsatellite instability are crucial for prognosis and targeted therapies in mCRC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Metastatic colorectal cancer (mCRC) diagnostics are evolving.
- Historically, RAS mutations were the primary focus.
- Emerging molecular markers significantly impact patient outcomes.
Purpose of the Study:
- To review recent molecular diagnostic advances in mCRC.
- To discuss the therapeutic implications of these molecular alterations.
- To explore novel diagnostic strategies for mCRC.
Main Methods:
- Literature review of recent studies on mCRC molecular diagnostics.
- Analysis of prognostic and therapeutic relevance of molecular markers.
- Discussion of emerging diagnostic technologies.
Main Results:
- BRAF mutations, HER2 amplification, and microsatellite instability are increasingly important in mCRC.
- These markers offer prognostic value and guide targeted treatment selection.
- Novel diagnostic approaches are enhancing precision medicine for mCRC.
Conclusions:
- Molecular profiling is essential for personalized mCRC treatment.
- Understanding BRAF, HER2, and MSI status improves therapeutic strategies.
- Future directions involve integrating advanced molecular diagnostics into routine clinical practice.
